Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib 160 mg in EGFR-Mutant Advanced NSCLC With Stable Disease
NCT07298148Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07298148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298148.